Veradermics
Last verified 2026-04-29. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $261.2Mattributed |
|---|---|
| Latest round | series-b, $75.0M, 2024-12-01attributed |
| Founded | 2019 |
| Headquarters | New Haven, United States |
| Industry | bio |
| Stage | series-b+ |
| Website | veradermics.com |
Veradermics is developing VDPHL01, a non-hormonal oral therapy for pattern hair loss, running three Phase 3 trials including the first US Phase 3 in female pattern hair loss. It targets men and women who want an oral alternative to topical minoxidil or hormonal finasteride. Large placebo-controlled trials aim for the first oral approval here in nearly 30 years.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-12-01 | series-b | $75.0M | undisclosed |
Detected tech stack
Nginx, WordPress 7.0, Magnific Popup 1.1.0, Yoast SEO 27.5, Google Tag Manager, imagesLoaded 5.0.0, Plesk, CookieYes, OWL Carousel, WP Rocket, PHP, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $75.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $261.2M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | veradermics.com, read 2026-04-29 |
| Description | self-reported | veradermics.com, read 2026-04-29 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.